170 related articles for article (PubMed ID: 3082756)
1. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Furer E; Sadoff JC; Germanier R
Infect Immun; 1986 Apr; 52(1):161-5. PubMed ID: 3082756
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
[TBL] [Abstract][Full Text] [Related]
3. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
Cryz SJ; Lang AB; Sadoff JC; Germanier R; Fürer E
Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
Cryz SJ; Sadoff JC; Fürer E; Germanier R
J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
6. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Fürer E
Microb Pathog; 1989 Jan; 6(1):75-80. PubMed ID: 2733597
[TBL] [Abstract][Full Text] [Related]
7. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.
Cryz SJ; Cross AS; Sadoff JC; Fürer E
Infect Immun; 1990 Feb; 58(2):373-7. PubMed ID: 2105272
[TBL] [Abstract][Full Text] [Related]
9. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1981 Nov; 34(2):461-8. PubMed ID: 6171520
[TBL] [Abstract][Full Text] [Related]
10. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Que JO; Cross AS; Fürer E
Vaccine; 1995 Apr; 13(5):449-53. PubMed ID: 7639013
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.
Tsay GC; Collins MS
Infect Immun; 1984 Jul; 45(1):217-21. PubMed ID: 6429046
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Sadoff JC; Ohman D; Fürer E
J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.
Cryz SJ; Sadoff JC; Fürer E
Infect Immun; 1988 Jul; 56(7):1829-30. PubMed ID: 2454893
[TBL] [Abstract][Full Text] [Related]
15. Immunologic basis for mouse protection provided by high-molecular-weight polysaccharide from immunotype 1 Pseudomonas aeruginosa.
Markham RB; Pier GB
Rev Infect Dis; 1983; 5 Suppl 5():S957-62. PubMed ID: 6419317
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide.
Pier GB; Bennett SE
J Clin Invest; 1986 Feb; 77(2):491-5. PubMed ID: 3080477
[TBL] [Abstract][Full Text] [Related]
17. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
Cryz SJ; Sadoff JC; Que JU
Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
[No Abstract] [Full Text] [Related]
18. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines.
Shapiro DA; Threadgill DS; Copfer MJ; Corey DA; McCool TL; McCormick LL; Magnuson TR; Greenspan NS; Schreiber JR
J Immunol; 1998 Oct; 161(7):3393-9. PubMed ID: 9759856
[TBL] [Abstract][Full Text] [Related]
19. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
Pier GB; Sidberry HF; Sadoff JC
Infect Immun; 1978 Dec; 22(3):919-25. PubMed ID: 103841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
